[Event Report] The 59th Breakfast Meeting:Technology Innovation and HTA
date : 10/28/2016
The theme for this breakfast meeting was “Technology Innovation and Health Technology Assessments (HTA).” GraSPP Prof. Akio Onishi talked about Japan’s health care system, as well as the future of health policies and how they compare with health systems in other countries.
[ Summary ]
Innovation and health care systems
The period from 1980 to 1990 saw the creation of a foundation for biotechnology, electronics, and materials technology, as well as the development of biogenetic modification techniques (the first human genome analysis was completed in 2000).
This was also when people began to consider ways to adopt new pharmaceuticals and medical technology into health care systems, along with progress in technology.
In the United States, people began to notice the differences between pharmaceuticals and medical technology. Progress was made on the reconsideration of the systems used to evaluate drug safety and efficacy, leading to the passage of the FDA Modernization Act in 1997.
In addition, in terms of medical payments, the Diagnosis Related Group (DRG) system was introduced in 1983 to evaluate medical fees based on the diagnoses given rather than the methods or processes of treatment used.
As a general rule, this system means that payments to hospitals are decided not per medicine, device and procedure, but per diagnosis code.
The difference between pharmaceuticals and medical technology
Pharmaceuticals and health technology have greatly different properties. While pharmaceuticals are developed from “discovered” substances, and then become recognized after being patented, health technology is “developed” and recognized once it shown to have a new structure or mechanisms that allow it to demonstrate new properties and effects and so on. Therefore, new health technology does not always result in a new patent.
The execution of clinical trials is also a big difference here.
With pharmaceuticals, it is usually not difficult to return to a normal treatment even if the clinical trial is stopped, but with implanted health technology, for instance, it is not easy to stop treatment due to the risks associated with removing the health technology from the body.
The health care system in Japan
In Japan, up until the Pharmaceutical Affairs Act and the Pharmaceuticals and Medical Devices Act were amended in 2014, health technology was regulated based on the Pharmaceutical Affairs Act, which reflected thinking about the regulation of pharmaceuticals.
Regulations for regenerative medicine devices were also applied.
In addition, regarding the insurance system, methods for evaluating medical payments, drug costs, and materials prices (including some health technology) have thus far been amended every two years. Some are now saying that medical costs will rise to 1.5 times what they are today over the next ten years due to the aging of society and technological innovations.
A variety of discussion is underway to consider the use of HTA and other systems.
Initiatives and future prospects for health care assessments
In addition to considering how we should evaluated the usefulness of individual technologies and products via HTA, it is also crucial to consider the evaluation of improvements in the quality of medical care brought about by the different ways people use products and technology in the midst of health care frameworks.
We are seeing the start of movement on initiatives for assessment systems that take into account outcomes that can measure this, having set the quality of medical care as the goal for medicine.
I am excited for this trend.
Exhibition date:2016-10-14
Top Research & Recommendations Posts
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Healthcare DX Project Research Report of Interviews ”Expectations for the Coming Era of Healthcare DX from People Living with Health Concerns” (June 10, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Patient and Public Involvement (PPI) Support Project “Promoting PPI in the Policymaking Process” (May 14, 2024)
- [Public Comment Submission] “The Fifth Fundamental Plan for Establishing a Sound Material-Cycle Society (Draft)” (May 22, 2024)
- [Policy Recommendations] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2024 (June 11, 2024)
Featured Posts
-
2024-06-21
[Event Report] HGPI Special Seminar – HGPI Celebrates its 20th Anniversary: Reflecting on HGPI’s Journey from the Past to the Future (January 16, 2024)
-
2024-06-25
[Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
-
2024-06-26
[Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
-
2024-06-26
[Registration Open] (Webinar) The 127th HGPI Seminar: Current Issues and Future Prospects in Establishing a Health System and Protecting Public Health Through Policy (July 18, 2024)
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)